Member Info for Rocket79

Fantastic guy well done. 188p Target will be blown out the water. Parsortix system can differentiate between women with a malignant pelvic mass and those with benign tumours with a high degree of sensitivity (correctly identifying cancer) of up to 95% whilst at the same time achieving a higher specificity (low false positive rate) than existing tests.

Andrew D Newland holds 7,054,686 shares. That's shows confidence.

This will rise up to results and rerate if positive. Buying at this level is a bargain imo. Good luck

188P TARGET http://www.edisoninvestmentresearch.com/research/report/angle809878/preview/#js

Proactive interview with AN hTTps://www.youtube.com/watch?v=loaJ7XLOlhU

Yes I agree this news is company changing. Expecting share price to rise considerably. Takeover now possible also.

I have sold up and bought some Angle AGL. Great news today and more news to come before end of June. Dyor Good luck all

HTtp://www.edisoninvestmentresearch.com/research/report/angle809878/preview/#js Angle H117 business update revealed that R&D activities are progressing well, while the company booked further research use sales. The first prospective clinical studies with Angle liquid biopsy system Parsortix in ovarian cancer reported positive early evaluation results and are due to report headline data in Q217. Our SOTP-based valuation is increased modestly to£140.3m or 188p/share. The main 2017 catalysts are the results from the ovarian cancer studies; an acceleration of research use sales; any new data from Angle multiple KOLs and customers investigating Parsortix; and progress with the FDA analytical and clinical studies.

188P TARGET HTtp://www.edisoninvestmentresearch.com/research/report/angle809878/preview/#js Angle H117 business update revealed that R&D activities are progressing well, while the company booked further research use sales. The first prospective clinical studies with Angle liquid biopsy system Parsortix in ovarian cancer reported positive early evaluation results and are due to report headline data in Q217. Our SOTP-based valuation is increased modestly to £140.3m or 188p/share. The main 2017 catalysts are the results from the ovarian cancer studies; an acceleration of research use sales; any new data from Angle multiple KOLs and customers investigating Parsortix; and progress with the FDA analytical and clinical studies

Voucher codes was bought for around £50 mil . Im expecting a bidding war also. Bid Price is far too low. Im holding as this could get vert interesting. Good luck all

MVC was bought for £49 Million. Now with revenue increasing to over £7.0 M and ebitda increasing MVC should be worth at least £150 M on its own. Buy the dips and do your own research. Good luck all

A mention in the Telegraph today.

Yes I'm buying. Angle is under radar of most private investors just how I like it.

Could be first contract. Shows validation of Finkit. First time I have seen this on website. Good luck all

Yes I'm also very excited about the future of Monitise. Listened to a radio program on fintechs bbc radio 4. Monitise are doing the right thing, patience required holders will be rewarded many times over from current levels imo. Good luck and God bless all

Fantastic....excellent find thanks. Exciting times ahead.

Results in next 4 weeks. I expect these to keep rising in anticipation. The results will be transformational if positive. I'm thinking they will be after reading the latest reports. Do your own research though. Good luck all

After reading the presentation posted by Noise I am very confident Monitise are on the right path. Patience will reward holders imo good luck all

Quiet here considering the excellent news. Fingers by the buy button : )

No it was on very low volume. Looked like market makers were fishing for stop losses. Expect this to recover to over 50p by Friday